TITLE

Of actors, bolting horses, and rops in oceans!

AUTHOR(S)
Cremonini, F.; Camilleri, M.
PUB. DATE
May 2003
SOURCE
Gut;May2003, Vol. 52 Issue 5, p619
SOURCE TYPE
Academic Journal
DOC. TYPE
Article
ABSTRACT
Examines whether serotonin mediates postprandial symptoms in irritable bowel syndrome (IBS). Components of the colonic contractile response to meals of IBS patients; Reasons behind the differences in circulating serotonin levels in IBS.
ACCESSION #
9737005

 

Related Articles

  • Increased platelet depleted plasma 5-hydroxytryptamine concentration following meal ingestion in symptomatic female subjects with diarrhoea predominant irritable bowel syndrome. Houghton, L.A.; Atkinson, W.; Whitaker, R.P.; Whorwell, P.J.; Rimmer, M.J. // Gut;May2003, Vol. 52 Issue 5, p663 

    Background: Meal ingestion is often associated with exacerbation of gastrointestinal symptoms in subjects with irritable bowel syndrome (lBS). Furthermore, recent preliminary data suggest that 5-hydroxytryptamine (5-HT) concentration in platelet poor plasma is elevated following meal ingestion...

  • Serotonin's Role in IBS.  // BioWorld Today;5/10/2010, Vol. 21 Issue 89, Special section p2 

    The article reports on the serotonin gene variants identified by a research team at Mayo Clinic which impact irritable bowel syndrome (IBS).

  • Incidence of colonic ischemia, hospitalized complications of constipation, and bowel surgery in relation to use of alosetron hydrochloride. Miller, David P.; Alfredson, Tanya; Cook, Suzanne F.; Sands, Bruce E.; Walker, Alexander M. // American Journal of Gastroenterology;May2003, Vol. 98 Issue 5, p1117 

    : ObjectiveAlosetron hydrochloride (Lotronex), a potent selective 5-hydroxytryptamine3 receptor antagonist, was approved in February, 2000 in the United States for the treatment of diarrhea-predominant irritable bowel syndrome (IBS) in women. Marketing was suspended in November, 2000, after...

  • EVIDENCE FOR INCREASED POST-PRANDIAL PLASMA 5-HYDROXYTRYPTAMINE (5-HT) CONCENTRATION IN FUNCTIONAL DYSPEPTICS AND RELATIONSHIP TO GENDER AND SYMPTOMS. Lea, R.; Houghton, L.A.; Whorwell, P.J.; Whitaker, P. // Gut;Apr2003 Supplement 1, Vol. 52, pA84 

    Recent studies suggest that patients with irritable bowel syndrome lBS have elevated levels of plasma 5-HT following meal ingestion compared with healthy controls. Moreover, patients who exhibit postprandial symptoms have higher plasma 5-HT levels compared with those who do not, suggesting a...

  • Tegaserod: A Viewpoint by Peter J. Whorwell. Whorwell, P.J. // Drugs;Sep1999, Vol. 58 Issue 3, p497 

    Comments on a study on the use of serotonin drug in the treatment of irritable bowel syndrome (IBS). Background of IBS; Use of tegaserod in the treatment of IBS; Problems regarding the development of drugs for the treatment of IBS.

  • Tegaserod: A Viewpoint by M. Scott Harris. Harris, M.S. // Drugs;Sep1999, Vol. 58 Issue 3, p497 

    Discusses a study on the use of tegaserod serotonin drug in the treatment of irritable bowel syndrome. Symptoms and manifestation of the disease; Diagnosis and treatment; Mechanism of action of tegaserod.

  • Tegaserod. Scott, L.J.; Perry, C.M. // Drugs;Sep1999, Vol. 58 Issue 3, p491 

    â–´ Tegaserod is a serotonin (5-hydroxytryptamine; 5-HT) receptor partial agonist which has been investigated for the treatment of irritable bowel syndrome (IBS). Specifically, it binds with high affinity to human 5-HT receptors, thereby stimulating the release of neurotransmitters and the...

  • Tegaserod. Wagstaff, Antona J.; Frampton, James E.; Croom, Katherine F. // Drugs;2003, Vol. 63 Issue 11, p1101 

    The treatment of irritable bowel syndrome with constipation (IBS-C) has historically been based on the severity of symptoms, with education, reassurance, dietary advice, bulking agents and laxative therapy offered as appropriate. Tegaserod (Zelnorm®, Zelmac®) is the first selective...

  • Serotonin transporter gene polymorphism in irritable bowel syndrome. Pata, Cengiz; Erdal, M. Emin; Derici, Ebru; Yazar, Aziz; Kanık, Arzu; Ulu, Oğuz // American Journal of Gastroenterology;Jul2002, Vol. 97 Issue 7, p1780 

    OBJECTIVES:Serotonin is a key mediator of intestinal peristalsis, and after it is secreted, it is effectively cleansed from the neuronal gap by means of a high affinity substance called serotonin transporter (SERT), which depends on the Na+ and Cl− ions localized in the presynaptic...

Share

Read the Article

Courtesy of VIRGINIA BEACH PUBLIC LIBRARY AND SYSTEM

Sign out of this library

Other Topics